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Colorectal cancer meets requirements justifying mass screening
(European Group for Colorectal Cancer Screening, 1999). Colo-
rectal cancer is usually preceded for many years by an asympto-
matic adenoma; the endoscopic resection of adenomas decreases
colorectal cancer incidence between 85% and 90% (Winawer et al,
1993). Currently, the faecal occult blood test HemoccultII® is the
only efficient test for screening. 3 prospective controlled cohort
studies in well-defined European populations aged 45 to 74 years
have demonstrated a decrease in specific colorectal cancer
mortality between 14% and 18% with a biennial HemoccultII® test
and a median follow-up of 8 to 10 years (Hardcastle et al, 1996;
Kronborg et al, 1996; Faivre et al, 1999). 
Besides determining the incidence of interval cancers by 
age-sex-subsite and time since a negative screen, this study aimed
to estimate HemoccultII® test sensitivity and mean sojourn 
time from a screening programme based on a biennial test (6
campaigns) in a well-defined French population covered by the
Burgundy registry of digestive tract cancers (Faivre et al, 1999). 
MATERIALS AND METHODS 
The study design has been described previously (Tazi et al, 1997).
All residents (n = 45 603) of 12 administrative districts of the
department of Saône-et-Loire (Burgundy, France), born between
1914 and 1943 (aged 45–74 years), were invited to participate in a
mass screening programme for colorectal cancer. A faecal occult
blood test, the HemoccultII® test (SKD, France), was used as a
screening test. The first round of mass screening took place in
1988 or 1989. The screening rounds were repeated for the whole
population in 1990, 1992, 1994, 1996 and 1998. All data were
recorded from 1 January 1988 until 31 December 1998, the closing
date of the study. A colonoscopy was offered if the test was 
positive. 
Subsite was defined for each cancer as: right colon (from the
caecum to the transverse colon), left colon (from the splenic
flexure to the sigmoid) or rectum (from the recto-sigmoidal junc-
tion to the rectal ampulla). In the screening programme popula-
tion, cancers were classified in 3 groups: cancers diagnosed from a
positive HemoccultII® test, interval cancers diagnosed after a
negative HemoccultII® test and cancers in those who did not
participate in any of the 6 screening rounds. Adenomas detected
by screening were classified according to the site (as for cancers in
3 groups) and size (millimetres). Polyps other than adenomas were
excluded. 
Statistical methods 
The statistical approach used in this article followed the same line
of thinking as that in previous publications treating the same
problem for breast cancer screening and mammography (Day and
Walter, 1984; Day 1985; Paci and Duffy, 1991). For the prevalent
screen (first screen attended by a participant), the cancer preva-
lence at screening was compared to the corresponding age-
sex-subsite-specific control population incidence rate, through the
prevalence/incidence ratio. This ratio gave a rough estimate of the
product of the mean sojourn time by the sensitivity (Day, 1985). A
second approach evaluated the incidence of interval cancer as a
function of time since the last negative screen and this incidence
was compared to the expected incidence in the absence of
screening (i.e. control population incidence). More precisely, all
participants with a negative test at either a prevalent or an incident
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death or occurrence of a colo-rectal cancer. Person-years at risk
broken down by age, sex, type of screen, and time since screen
were calculated using the STATA statistical software and its survival
procedures (StataCorp. 1999. Stata Statistical Software: Release
6.0. College Station, TX: Stata Corporation). Expected incidence
was then calculated by applying the age-sex-subsite-specific rate
of the control population (Table 1). The above-cited references
show that the ratio observed/expected cancers after a negative test
provides information on test sensitivity and the distribution of
sojourn time. This ratio is known as proportional incidence. In
particular, this ratio calculated in a short period after a negative
screen test is a rough approximation of one minus the sensitivity:
the higher the ratio the lower the sensitivity (Moss et al, 1999). As
shown in the appendix, the information on the sojourn time is
mainly contained in the increase of this ratio with time since
screening. In order to work with independent observations, we
used the formula: 
where Ot,∆ t and Et,∆ t, are respectively observed and expected cancer
within the intervals ]t – ∆ t; t + ∆ t[, and S is the sensitivity of the
test and l the inverse of the mean sojourn time (see Appendix). We
then obtained estimates of S and l through a simple weighted
least-square regression based on observed data in short intervals
following a negative screen. In principle we should have taken into
account the screen performed before the last negative screen and
entered into our formula the fact that a cancer could have been
missed already by the previous screening. This refinement is of
interest but would have had little effect on our results given that
only a few cancers have a sojourn time larger than 2 years and that
few persons in the cohort attended all screening rounds. 
RESULTS 
The number of screened individuals and the number of detected
colorectal cancers by sex at each screening round are detailed in
Table 2. From the 45 603 individuals of the study cohort only 11
851 (26.0%) attended all screening rounds, but 31 664 individuals
(69.4%) attended at least one round. Compliance at each round
was higher for women. At the end of the study 195 colorectal
cancers were detected, 128 in men (65.6%) and 67 in women
(34.4%). Interval cancers were diagnosed in 294 individuals,
among whom 6 were diagnosed after a negative test in the last
round for which the follow-up was shorter. There were 171
interval cancers in men (58.2%) and 123 in women (41.8%). In
men 125 interval cancers (73.1%) were diagnosed within 2 years
of a negative screen. In women there were 95 such interval cancers
(77.2%). 
Table 3 shows the cancers detected at prevalent screens by sex
and subsite. From this table we can see that the ratio observed/
expected was significantly higher in men than in women (c2 =
5.44; P = 0.02). In men there was some evidence of heterogeneity
between subsites suggesting that the sojourn time was longer or
that sensitivity was higher, or both, for the left colon than for the
other subsites (c2 = 3.85; P = 0.05 if the left colon is compared to
the other sites). There is no such difference in women but the
number of cases is too small to interpret this result further. 
Table 4 analysed the incidence of the interval cancers by
subsite: the proportional incidence was lower for the left colon
than for the other subsites and increased between year 1 and year 2
confirming both the above result from prevalence analysis and
what is known from the literature. However the differences were
not significant. There was no difference in proportional incidence
between sexes (0.61 for males and 0.64 for females). Although
some differences were seen for age (0.67 for peoples aged 45–64
years and 0.59 for those aged under 65 years) and type of screen
(0.70 for first screen and 0.59 for rescreen), none of them were
significant. 
The joint estimates of S and l were obtained from the results
shown in Table 5. We performed a regression as explained in the
method section (equation 3) on the first 3 values of Ot/Et for which
an increase of the proportional incidence is seen. This approach
gave an estimate of S equal to 0.57 (SE = 0.10) and an estimate of
l equal to 0.39 (SE = 0.19) corresponding to a mean sojourn time
of 2.56 years. When different parameters for men and women were
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Table 1 Incidencea of colorectal cancer in the department of Saône-et-Loire without screening for people aged 45–75 years and
more, according to subsite, sex and age 
Age (years) Right colon Left colon Rectum  Subsite unknown Overall 
Males 
45–49 4.3 6.4 12.8 0.0 23.4 
50–54 9.9 16.8 31.7 0.0 58.5 
55–59 15.8 31.6 53.3 4.0 104.7 
60–64 23.6 50.5 88.7 4.5 167.4 
65–69 65.6 85.1 102.8 3.5 257.0 
70–74 62.5 99.3 184.2 1.6 347.5 
³ 75 91.3 167.2 221.1 7.7 489.5 
Females 
45–49 3.2 8.7 10.8 1.1 23.8 
50–54 2.9 21.5 14.7 1.0 40.1 
55–59 14.1 30.2 23.6 0.9 68.8 
60–64 17.4 36.9 42.1 1.0 97.5 
65–69 37.9 58.3 40.8 0.0 137.0 
70–74 57.0 57.0 55.8 0.0 169.8 
³75 94.9 77.1 80.0 1.8 254.9 
aIncidence rate per 100 000 using 1982–1987 Digestive Cancer Registry data. 
Log (1-Ot, Dt) = Log (S) - lt Et, Dtestimated we obtained S equal to 0.57 and MST equal to 3.21 
for men and 0.63 and 1.51 respectively for women. In both 
cases the negative correlation of these 2 parameters was large 
and the individual estimate not very reliable. In contrast they
provided a reasonable estimate of the product S.MST. This latter
parameter, 1.83 in men and 0.95 in women, is in broad agreement
with the estimates obtained from the prevalence/incidence 
ratio. 
The sensitivity of the screening programme was calculated for 1
and 2 years time intervals following a negative test. The overall
sensitivity of the screening programme was 0.61 within 1 year and
0.43 within 2 years (169 screened-detected and 220 interval
cancers). The sensitivity of the screening programme according to
screening round within 1 year after a negative test is given in Table 6.
It was slightly higher after the first screening round than after the
following ones. 
DISCUSSION 
Screening for colorectal cancer with the HemoccultII® test has
proved to be efficacious through 2 population-based intervention
trials (Hardcastle et al, 1996; Kronborg et al, 1996) and one inter-
vention based on a selected group of volunteers (Mandel et al,
1993). A recent meta-analysis estimates that the reduction in
mortality may be in the range of 16% to 20% (Towler et al, 2000)
a relatively small benefit. In the 2 above-cited population-based
trials the sensitivity of the programme among the participants was
55% in Funen (Gyrd-Hansen et al, 1997) and 51% in Nottingham
(Moss et al, 1999). The data of the present intervention led to
results of the same order of magnitude but slightly smaller
(43.4%). In contrast with this broad agreement on efficacy there is
a wide range in the various sensitivity estimates of the test (Gyrd-
Hansen et al, 1997; Launoy et al, 1997; Moss et al, 1999) ranging
from 22% to 90% (Moss et al, 1999). Even if we restrict the review
to population-based study we obtain a large range of estimates
(34% to 75%). One obvious reason for these discrepancies lies in
the lack of a uniform definition of sensitivity. If sojourn time starts
when the cancer bleeds, the sensitivity of the test is the probability
that the cancer is bleeding at the time of the test. It is unlikely that
this quantity is constant over the sojourn time, thereby bringing
into question the adequacy of the model. If we accept its use, the
resulting estimate of sensitivity should be considered as the
portion of the sojourn time during which the cancer is bleeding.
With this caveat in mind our findings can be compared with results
obtained elsewhere. All studies agree in showing that screening is
more efficient for detecting tumours in the left colon. In practice it
is more easy to diagnose distal than proximal tumours and colo-
noscopy may fail to explore the entire colon. In the present study,
the colonoscopy was not performed after a positive test in 412
cases (20.7%) and did not go beyond the hepatic flexure in 134
cases (6.8%). As a consequence the sensitivity of the procedure is
more limited for the right colon than for other sites. The observed
difference in proportional incidence and in the prevalence/
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Table 2 Screened population and screened detected colorectal cancers by screening round and sex 
Screening  Number screened Cancers detected
round Male Female Both sexes Male Female Total 
1 10 770 13 288 24 058 30 10  40 
2 10 590 13 070 23 660 13 11  24 
3 10 512 13 172 23 684 25 13  38 
4 9 975 12 659 22 634 22 12  34 
5 9 204 11 823 21 027 22 11  33 
6 8 177 10 551 18 728 16 10  26 
Total 59 228 74 563 133 791 128 67 195 
Table 3 Observed and expecteda number of colorectal cancers after the
first positive test (prevalent screening) by sex and subsite 




Right colon 9 4.5 2.0 
Left colon 23 8.0 2.9 
Rectum 19 12.3 1.5 
All sites 51 24.8 2.1 
Females 
Right colon 6 4.9 1.2 
Left colon 8 6.6 1.2 
Rectum 6 6.2 1.0 
All sites 20 17.7 1.1 
Both sexes 
Right colon 15 9.4 1.6 
Left colon 31 14.5 2.1 
Rectum 25 18.6 1.3 
All sites 71 42.6 1.7 
aAge-standardized expected number of cases without screening using
1982–1987 Saône-et-Loire Digestive Cancers Registry data. 
Table 4 Proportional incidence of colorectal cancer after a negative test by
subsite 
Subsite Person-years Observed Expected Proportional   
interval cases (E) incidence
cases (O) O/E
Rectum 
Year 1 126 313 52 82.8 0.63 
Year 2 99 868 46 68.0 0.68 
Total 226 181 98 150.8 0.65 
Left colon 
Year 1 126 313 29 66.7 0.43 
Year 2 99 868 38 54.6 0.70 
Total 226 181 67 121.3 0.55 
Right colon 
Year 1 126 313 33 44.4 0.74 
Year 2 99 868 21 36.7 0.57 
Total 226 181 54 81.1 0.67 
Subsite is unknown for 1 interval cancer. incidence ratio may therefore be explained by a lower sensitivity
of the test rather than by a shorter sojourn time. In contrast the
studies disagree on the size of the difference between male and
female and in the direction of this difference. Proportional inci-
dence is slightly higher in females and increases with time since
screening in both the Funen study (Gyrd-Hansen et al, 1997) and
our study. It is significantly smaller in females than in males in the
Nottingham study and does not increase with time. The Calvados
results (Launoy et al, 1997) are qualitatively similar to those of
Nottingham. It is difficult to understand these discrepancies but
the random fluctuations of the number of cases are too large to
permit a more satisfactory analysis. 
There are few reports on the analysis of the prevalence/
incidence ratio for colo-rectal cancer screening. In the Funen
programme, the ratio was close to one and slightly higher for men
than for women. In the above Calvados study, the prevalence/inci-
dence ratio was calculated differently and does not directly
provide an S.MST estimate, but this can be inferred as smaller in
value and slightly higher for males. In our study the ratio is also
greater for men and the results are in broad agreement with those
obtained from the proportional incidence analysis. 
When using the prevalence/incidence ratio to estimate S.MST
we were not able to take into account prevalence or incidence of
adenoma. Therefore an estimate refers only to the MST of the
tumour when it has become malignant and to the sensitivity of the
test to detect cancer. On the other hand the cumulative incidence of
interval cancer is influenced by the ability of the test to detect
adenoma. However the duration of the adenoma-cancer sequence
is considered to be longer than 10 years. Therefore the part of the
cumulative incidence which is used in our calculation is only
influenced by the ability of the test to detect cancer. As a conse-
quence, both approaches for estimation of S and MST refer to the
asymptomatic cancer part of the sojourn time. Although it is
necessary to assess the efficacy of Hemoccult to decrease the inci-
dence of cancer through the detection of adenoma, our approaches
and data did not permit this evaluation. 
The sensitivity of the programme among participants is lower in
Burgundy than in either Denmark or England. Among other expla-
nations, differences in the sensitivity of the test and in sojourn time
may be relevant. In particular the increase in sojourn time may be
due to delayed diagnosis of symptomatic cancer, which in turn
could explain a larger benefit of screening. It is therefore impor-
tant to have information on these 2 parameters. Unfortunately all
studies up to now have demonstrated the difficulties in obtaining
reliable estimates of sensitivity and mean sojourn time due to their
strong inverse relation and the relatively small study sizes. One
other reason for the lower sensitivity of the programme in
Burgundy is the relatively weak compliance for only 26% of the
cohort attended all the screening rounds. This explanation is
consistent with the relatively high proportion of Hemoccult
detected cancers among the interval cancer in the first year after a
negative screen (61%). 
Several simple estimates of sensitivity have been proposed,
including the proportion among the total of those detected on a
positive screen or diagnosed on symptoms within one year of a
negative screen. These estimates are given in Table 6 and are not
too far from those obtained with the simple regression performed
on proportional incidence. We think on the contrary that the 
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Table 6 Estimate of test sensitivity by screening round according to interval cancers
occurring within one year after a negative test 
Screening round Screen-detected  Interval cancers  Sensitivity (%) 
cancers within one year
1 40 15 72.7 
2 24 23 51.1 
3 38 30 55.9 
4 34 15 69.4 
5 33 25 56.9 
Total 169 108 61.0 
Table 5 Proportional incidence of colorectal cancer after a negative test 
Time since a negative screen (years) 
0.5 1 1.5 2 2.5 3 
Males 
Observed interval cases 29 36 30 30 11 3 
Expected cases 59.3 55.2 49.2 45.0 12.9  6.9 
S Obs/ S Exp 0.49 0.57 0.58 0.60 0.61 0.61 
Females 
Observed interval cases 24 25 28 18 6 3 
Expected cases 42.4 39.4 35.0 32.0 9.7 5.1 
S Obs/ S Exp 0.57 0.60 0.66 0.64 0.64 0.64 
Both sexes 
Observed interval cases 53 61 58 48  17 6 
Expected cases 101.7 94.6 84.2 77.0  22.6 12.0 
S Obs/ S Exp 0.52 0.58 0.61 0.62 0.62 0.62 
S Obs: cumulated observed interval cases; S Exp: cumulated expected cases. estimate based on 1–Ot/Et is generally too low especially if the
sojourn time is exponentially distributed: with a 2-year mean
sojourn time, 40% of cancers have a sojourn time less than 1 year. 
For the practical purpose of managing and designing mass
screening programmes we consider that the sensitivity of the
Hemoccult test is near to 60% and that the mean sojourn time is
about 2 years, but these estimates need to be refined in more
precise studies. 
APPENDIX 
If we were to suppose that in a given age-sex-subsite category the
incidence rate in the absence of screening is constant, the prob-
ability that a new cancer surfaces within the interval ]0,t] after a
negative screen is: 
I is the constant incidence of cancer in the absence of screening
and ST is the sojourn time. The integral is the sum of the prob-
ability of occurrence of a cancer with a sojourn time less than u at
time u; the first factor is the probability of occurrence of a cancer
of the given age-sex-subsite within the interval ]0,t]. 
All other cancers with a sojourn time greater than u could have
been detected or missed with a probability S and 1–S respectively.
Therefore the probability of observing an incident cancer in the
interval ]0,t] is: 
where F(u) is Pr (ST ≤ u). 
When I ´ t is small, the first factor is well approximated by I
itself. Moreover if we believe that an exponential distribution for
the sojourn time is acceptable the formula simplifies and we obtain
the cumulative distribution of interval cancer after a negative
screen as: 
where l is the inverse of the mean sojourn time. 
From this formulation we can see that the ratio of the interval
cancer incidence to that expected in the absence of screening,
known as the proportional incidence, is given by: 
which for small lt is approximated by 1–S + Sl t/2–Sl2 t2/6. It is
possible to estimate this distribution function from its density by
taking the derivative of (2): The number observed in a small
interval around t is proportional to I∆ t ´ (1–Se–lt) = E∆ t´ (1–Se–lt).
Therefore: 
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